For Positive PolypDx™ results: There is a strong likelihood of a polyp being present.

For Negative PolypDx™ results: There is a low likelihood of a polyp being present.

The benefits of PolypDx™ are:

• Early stage detection: PolypDx™ detects adenomatous polyps, the precursor to colorectal cancer, thereby detecting individuals at risk for colorectal cancer
• High patient compliance: PolypDx™ does not require any unpleasant bowel cleansing preparation, nor unsanitary handling of stool or blood collections.
• Ease of use: PolypDx™ is fast and simple to collect – just a small urine sample is required with no dietary or medication restrictions.
• Higher accuracy: PolypDx™ has superior performance characteristics for colonic adenomatous polyp detection. PolypDx™ was validated in clinical trial of nearly 1000 patients, demonstrating a high sensitivity for detecting adenomatous polyps.
• Cost-effective and high-throughput platform: PolypDx™ is a mass-spectrometer-based test, therefore allowing high-throughput and cost-effective population-based screening.

The risks of PolypDx™ are:

• There are no risks to completing PolypDx™. Only a small urine sample is required.

Clinical laboratories currently offering PolypDx™ testing include Atlantic Diagnostic Laboratories and Lab Express.

If you are interested in having PolypDx™ available at your local laboratory, please contact us.

Results will be sent back (via email or fax) within two weeks of the laboratory receiving the sample.

PolypDx™ is a noninvasive test designed to measure small molecules (metabolites) in urine samples to detect the presence of polyps in the colon and rectum. Using the science of metabolomics, specific metabolite concentrations are analyzed with a validated algorithm to determine the likelihood of a polyp being present.

Metabolomics is a new “omics” science which characterizes low molecular weight compounds generated by metabolism. Currently, there are over 40,000 known metabolites in the human body and their specific concentrations provide a snapshot of an individual’s current health state.

PolypDx™ is currently patient-pay, although reimbursement for the test is under discussions.

PolypDx™ is currently listed with a Proprietary Laboratory Analysis (PLA) code code, 0002U.

Please call Metabolomic Technologies Inc. at +1-587-772-1684. For patient information, visit the PolypDx™ patient page.